Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.42 |
| ▸ | BCHE | P06276 | 7/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878598 | 0.81 | AAK1 (0.41) | — | |
| SCHEMBL3866063 | 0.81 | ACHE (0.52) | ACHEBCHEFAAH | |
| SCHEMBL3868537 | 0.78 | ACHE (0.48) | ACHEBCHEFAAH | |
| SCHEMBL30878492 | 0.76 | KDM4E (0.44) | — | |
| SCHEMBL3869895 | 0.76 | ACHE (0.46) | ACHEBCHE | |
| SCHEMBL3873293 | 0.76 | ACHE (0.51) | ACHEBCHEFAAH | |
| SCHEMBL3870406 | 0.74 | CYP3A4 (0.36) | ACHEBCHEFAAHOPRK1 | |
| SCHEMBL3863046 | 0.74 | ACHE (0.45) | ACHEBCHE | |
| SCHEMBL3870281 | 0.74 | ACHE (0.40) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL3868386 | 0.74 | NPC1 (0.40) | ACHEBCHEFAAHOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | ACHE 4111/4885BCHE 1094/4885FAAH 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.